On June 9, 2022 Ancora Biotech reported Lightspeed Venture Partners and S.R. One have co-led a $60million series A round for Ancora Biotech LLC, which housesthree bispecific antibodies spun out from TeneoBio Inc (Press release, Ancora Biotech, JUN 9, 2022, View Source [SID1234618882]). Ancora will advance TNB-486, a bispecific T cell engagertargeting CD19 and CD3 that is in Phase I testing for B cellcancers; TNB-738, an anti-CD38 enzyme inhibitor formetabolic disorders currently in a study in healthy volunteers;and an HBsAg x CD3 bispecific for HBV. Amgen Inc.(NASDAQ:AMGN) paid $900 million up front for TeneoBiolast year. AbbVie Inc. (NYSE:ABBV) had previously boughtanother of the asset-focused biotech’s programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!